CHICAGO – Fresh off the FDA's April blessing of its plans to move the experimental metastatic pancreatic cancer therapy PEGPH20 into phase III early next year, Halozyme Therapeutics Inc. shared interim data from the ongoing second stage of its randomized phase II study of the drug at the ASCO meeting.